DelveInsight’s, “Nasal Polyposis Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Nasal Polyposis pipeline landscape. It covers the Nasal Polyposis pipeline drug profiles, including Nasal Polyposis clinical trials and nonclinical stage products. It also covers the Nasal Polyposis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For the Nasal Polyposis emerging drugs, the Nasal Polyposis pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). It provides a detailed description of each drug, including its mechanism of action, Nasal Polyposis clinical trial studies conducted for Nasal Polyposis, any NDA approvals obtained for Nasal Polyposis, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Nasal Polyposis Pipeline treatment landscape of the report, click here @ Nasal Polyposis Pipeline Outlook
Key Takeaways from the Nasal Polyposis Pipeline Report
- DelveInsight’s Nasal Polyposis Pipeline analysis depicts a robust space with 4+ active players working to develop 4+ pipeline treatment therapies.
- The leading Nasal Polyposis Companies are working in the market include AstraZeneca, Allakos, Idorsia Pharmaceuticals, Novartis, Regeneron Pharma, Sanofi, Amgen, GSK, CRF Health, Bristol-Myers Squibb, BioClinica Inc, Signant Health, and others
- Emerging Nasal Polyposis Pipeline Therapies in the various stages of development include Benralizumab 30 mg, Mepolizumab, Mometasone furoate, Dupilumab SAR231893, DUPIXENT, and others
- On June, 2023, Regeneron Pharmaceuticals has announced drug named DUPIXENT®. To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time.
- On May, 2023, AstraZeneca has announced drug named Tezepelumab by the phase 3. A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis.
- On March, 2023, Sanofi has announced drug named SAR231893 by the phase 4. This is a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately controlled with existing therapies.
Nasal Polyposis Overview
A nasal polyp (also called nasal polyposis) is a benign (noncancerous) tumor that grows from the lining of the nose or sinuses. These polyps usually occur in both the right and left nasal passages and obstruct the flow of air. They can make your nose feel stuffy, and can decrease your sense of smell. Not all growths in the nose are polyps.
For further information, refer to the detailed Nasal Polyposis Unmet Needs, Nasal Polyposis Market Drivers, and Market Barriers, click here for Nasal Polyposis Ongoing Clinical Trial Analysis
Nasal Polyposis Emerging Drugs Profile
- Benralizumab: AstraZeneca
- AK001: Allakos
Nasal Polyposis Pipeline Therapeutics Assessment
There are approx. 4+ Nasal Polyposis companies which are developing the therapies for Nasal Polyposis. The Nasal Polyposis companies which have their Nasal Polyposis drug candidates in the most advanced stage, i.e. phase III include AstraZeneca.
Request a sample and discover the recent advances in Nasal Polyposis Ongoing Clinical Trial Analysis and Medications, click here @ Nasal Polyposis Treatment Landscape
Nasal Polyposis Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Nasal Polyposis Therapeutics Market include-
AstraZeneca, Allakos, Idorsia Pharmaceuticals, Novartis, Regeneron Pharma, Sanofi, Amgen, GSK, CRF Health, Bristol-Myers Squibb, BioClinica Inc, Signant Health, and others.
Dive deep into rich insights for drugs for Nasal Polyposis Pipeline, click here @ Nasal Polyposis Unmet Needs and Analyst Views
Scope of the Nasal Polyposis Pipeline Report
- Coverage- Global
- Nasal Polyposis Companies- AstraZeneca, Allakos, Idorsia Pharmaceuticals, Novartis, Regeneron Pharma, Sanofi, Amgen, GSK, CRF Health, Bristol-Myers Squibb, BioClinica Inc, Signant Health, and others.
- Nasal Polyposis Therapies- Benralizumab 30 mg, Mepolizumab, Mometasone furoate, Dupilumab SAR231893, DUPIXENT, and others
- Nasal Polyposis Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Nasal Polyposis Merger and acquisitions, Nasal Polyposis Licensing Activities @ Nasal Polyposis Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Nasal Polyposis Executive Summary
- Nasal Polyposis: Overview
- Nasal Polyposis Pipeline Therapeutics
- Nasal Polyposis Therapeutic Assessment
- Nasal Polyposis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Nasal Polyposis Collaboration Deals
- late Stage Products (Phase III)
- Benralizumab: AstraZeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- AK001: Allakos
- Drug profiles in the detailed report…..
- Inactive Products
- Nasal Polyposis Key Companies
- Nasal Polyposis Key Products
- Nasal Polyposis- Unmet Needs
- Nasal Polyposis- Market Drivers and Barriers
- Nasal Polyposis- Future Perspectives and Conclusion
- Nasal Polyposis Analyst Views
- Nasal Polyposis Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit
